Type of publication:
Type of document:
Wressnigg, N; Pöllabauer, EM; Aichinger, G; Portsmouth, D; Löw-Baselli, A; Fritsch, S; Livey, I; Crowe, BA; Schwendinger, M; Brühl, P; Pilz, A; Dvorak, T; Singer, J; Firth, C; Luft, B; Schmitt, B; Zeitlinger, M; Müller, M; Kollaritsch, H; Paulke-Korinek, M; Esen, M; Kremsner, PG; Ehrlich, HJ; Barrett, PN
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Lancet Infect Dis (13), 8 680-689.
Authors Vetmeduni Vienna:
Lyme borreliosis is caused by Borrelia burgdorferi sensu stricto in the USA and by several Borrelia species in Europe and Asia, but no human vaccine is available. We investigated the safety and immunogenicity of adjuvanted and non-adjuvanted vaccines containing protective epitopes from Borrelia species outer surface protein A (OspA) serotypes in healthy adults.
Adjuvants, Immunologic/adverse effects* Adult Antigens, Surface/adverse effects* Antigens, Surface/immunology* Bacterial Outer Membrane Proteins/adverse effects* Bacterial Outer Membrane Proteins/immunology* Bacterial Vaccines/adverse effects* Bacterial Vaccines/immunology* Borrelia burgdorferi/immunology* Double-Blind Method Female Headache/chemically induced Humans Immunoglobulin G/blood Lipoproteins/adverse effects* Lipoproteins/immunology* Lyme Disease Vaccines/adverse effects* Lyme Disease Vaccines/immunology* Male Middle Aged Pain/chemically induced Young Adult